



ARSEUS
Driving superior care

Press release

Regulated information

Arseus successfully completes refinancing

Waregem (Belgium) / Rotterdam (the Netherlands)¹, 3 July 2012 – Arseus NV announces today that it has successfully completed a credit facility of € 300 million with ING Belgium (Coordinator), KBC Bank, BNP Paribas Fortis and Commerzbank. The new credit agreement has a term of 5 years and a revolving credit facility of € 300 million, divided into two tranches each of € 150 million. The main covenant of this credit facility is a net financial debt/recurring EBITDA ratio of a maximum of 3.25.

On 2 July 2012, Arseus NV issued € 225 million in bonds, consisting of 225,000 bonds with a nominal value of € 1,000 per bond. The bonds were listed on Euronext Brussels on 2 July 2012 under ISIN code BE0002180462. The bonds have a maturity of 5 years and offer a fixed annual gross interest of 4.75%. The bonds are redeemable on 2 July 2017 at 100% of the nominal value.

The proceeds of the bond issue are used by Arseus NV for the repayment of € 150 million of the € 300 million credit facility. The new credit facility of € 150 million at ING Belgium (Coordinator), KBC Bank, BNP Paribas Fortis and Commerzbank and the bond issue of € 225 million replace the credit facility of € 300 million that was agreed on 30 August 2007 and amended on 10 December 2010.

For more information:

Constantijn van Rietschoten
Director of Corporate Communications
+31 88 33 11 222 (office)
+31 6 536 91 585 (mobile)
constantijn.van.rietschoten@arseus.com

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

¹ This press release was sent out by Arseus NV and Arseus BV.

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in Europe, the US, Brazil and Argentina. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.